Our laboratory studies the mechanisms that initiate and perpetuate lung inflammation and remodeling, and ultimately lead to lung diseases such as asthma and pulmonary vascular disease. Studies aim to uncover the mechanisms that cause abnormalities in redox balance, signal transduction and/or accelerate arginine metabolism and impact nitric oxide (NO) production. The findings are all being applied to development of diagnostics and therapeutics for patient care.
Serpil Erzurum is Executive Vice President and Cleveland Clinic’s Chief Research and Academic Officer and Chair of the Lerner Research Institute. Dr. Erzurum focuses on strategic growth of enterprise-wide medical and scientific education programs; clinical, basic and translational research; and technology development to deliver the most innovative care to patients.
A practicing pulmonologist and active scientist, Dr. Erzurum holds the Alfred Lerner Memorial Chair in Innovative Biomedical Research. Her scientific contributions and leadership in pulmonary research have led to diagnostic and therapeutic advances in lung diseases and helped to identify human physiologic adaptive responses to high-altitude hypoxia. She has published more than 300 peer-reviewed articles and has been the principal investigator on more than 20 federal grants, including multi-investigator program project grants and network trials. She is also a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Erzurum has earned numerous awards, including the prestigious MERIT award from the National Heart, Lung and Blood Institute (NHLBI). She was elected to the National Academy of Medicine (NAM), American Society for Clinical Investigation (ASCI), andAssociation of American Physicians (AAP), where she served as president from 2017-2018. She has also served as chair of the Pulmonary Disease Board of the American Board of Internal Medicine (ABIM). Because of her work in advancing the careers of women in medicine and science, Dr. Erzurum was honored with the Elizabeth Rich Award from the American Thoracic Society.
Dr. Erzurum earned her medical degree from Northeastern Ohio Universities College of Medicine and completed residency training in internal medicine at Baylor College of Medicine. She completed fellowship training at the University of Colorado Health Sciences Center and postdoctoral training at the National Heart, Lung and Blood Institute in Bethesda, Maryland.
Education & Fellowships
Fellowship - National Heart, Lung and Blood Institute
Senior Staff Fellow, Pulmonary
Bethesda, MD USA
1992
Fellowship - University of Colorado Health Sciences Center
Pulmonary/Critical Care
Denver, CO USA
1990
Residency - Baylor College of Medicine
Internal Medicine
Houston, TX USA
1986
Medical Education - Northeastern Ohio Universities College of Medicine
Rootstown, OH USA
1983
Professional Highlights
Certifications
Awards & Honors
Memberships
Our laboratory studies the mechanisms that initiate and perpetuate lung inflammation and remodeling, and ultimately lead to lung diseases such as asthma and pulmonary vascular disease. Studies aim to uncover the mechanisms that cause abnormalities in redox balance, signal transduction and/or accelerate arginine metabolism and impact nitric oxide (NO) production. The findings are all being applied to development of diagnostics and therapeutics for patient care.
View publications for Serpil Erzurum, MD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.
Learn MoreOpens expanded research space and announces construction of two new research buildings
Cleveland Clinic researchers utilize artificial intelligence to create a discovery tool by outlining interactions between viral and host proteins.
The facility, the first new building in the Cleveland Innovation District, will be located in the Fairfax neighborhood and house 400 freezers for biological samples that will advance research.
Using patient data from Cleveland Clinic’s COVID-19 registry, Dr. Zein found that receiving the flu vaccine does not increase risk for COVID-19 or worsen associated disease outcomes, suggesting it is safe and advisable to receive the influenza vaccine this flu season.